Active Ingredient History
Sarilumab, sold under the brand name Kevzara, is a human monoclonal antibody medication against the interleukin-6 receptor. Regeneron Pharmaceuticals and Sanofi developed the drug for the treatment of rheumatoid arthritis (RA), for which it received US FDA approval on 22 May 2017 and European Medicines Agency approval on 23 June 2017. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Arthritis, Juvenile (Phase 2)
Atherosclerosis (Phase 4)
Breast (Phase 1/Phase 2)
Coronavirus Infections (Phase 3)
COVID-19 (Phase 3)
Dermatitis, Allergic Contact (Phase 2/Phase 3)
Giant Cell Arteritis (Phase 3)
Inflammation (Phase 2/Phase 3)
Lung Neoplasms (Phase 1)
Mastocytosis, Systemic (Phase 2)
Melanoma (Phase 2)
Neoplasm Metastasis (Phase 1/Phase 2)
Neoplasms (Phase 1/Phase 2)
Pneumonia, Viral (Phase 3)
Polymyalgia Rheumatica (Phase 3)
Sarcoidosis (Phase 2)
Severe Acute Respiratory Syndrome (Phase 2)
Skin Diseases (Early Phase 1)
Spondylitis, Ankylosing (Phase 2)
Triple Negative Breast Neoplasms (Phase 1/Phase 2)
Uveitis (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
